SCHEMBL19681474

SCHEMBL19681474

C[C@H](NC(=O)CCCCCN1C(=O)C=CC1=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 4/20 0.39
▸ NPY4R P50391 4/20 0.39
▸ NPY1R P25929 3/20 0.39
▸ PTGS1 P23219 5/20 0.36
▸ PTGS2 P35354 5/20 0.36
▸ NPY2R P49146 1/20 0.36
▸ NMT2 O60551 1/20 0.33
▸ NMT1 P30419 1/20 0.33
▸ AKT1 P31749 1/20 0.33
▸ FAP Q12884 1/20 0.32
▸ MGLL Q99685 2/20 0.32
▸ C3AR1 Q16581 1/20 0.32
▸ HSP90AA1 P07900 1/20 0.32
▸ TLR9 Q9NR96 1/20 0.32
▸ FAAH O00519 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20935177 0.93 NPY5R (0.35) NPY5RNPY4RNPY1RNPY2RAKT1
SCHEMBL22267878 0.91 FAP (0.37) NPY5RNPY4RNPY1RPTGS1PTGS2
SCHEMBL18909025 0.91 FAP (0.37) NPY5RNPY4RNPY1RPTGS1PTGS2
SCHEMBL22694922 0.91 FAP (0.37) NPY5RNPY4RNPY1RPTGS1PTGS2
SCHEMBL20340675 0.90 NMT1 (0.43) NPY5RNPY4RNPY1RPTGS1PTGS2
SCHEMBL19681473 0.90 NPY5R (0.42) NPY5RNPY4RNPY1RPTGS1PTGS2
SCHEMBL22668934 0.89 NPY4R (0.38) NPY5RNPY4RNPY1RPTGS1PTGS2
SCHEMBL23436462 0.88 NMT1 (0.46) NPY5RNPY4RNPY1RNPY2RNMT2
SCHEMBL20889000 0.88 NMT1 (0.46) NPY5RNPY4RNPY1RNPY2RNMT2
SCHEMBL22668929 0.88 PTGS1 (0.44) NPY5RNPY4RNPY1RPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348429-A1 ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE AbbVie Manufacturing Management Unlimited Company (IE) 2017-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348429-A1 ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE MMAB, HNMT, SHMT1 NPY5R 3964/4885NPY4R 4286/4885NPY1R 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback